Current Editions
Senators are trying to revive the Biosecure Act
Amendment seeks disengagement with Chinese biotechs, attempts to address concerns that killed Biosecure
Politics, Policy & Law
Guest Commentary
FDA delays mean more deaths: Ultrarare diseases need a fit-for-purpose pathway
The agency must act with urgency and not be trapped by standards that can only be met in large indications
Finance
More venture money for PD-1 x VEGF, new modalities: Finance Report
Plus: Public raises for Assembly, Sana and Shattuck
BioCentury ISSN 1097-7201